Drug intelligence / Profile preview

Lipichol

Development stage: Unknown
Lead developer: LIB Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Lipichol is a generic pharmaceutical drug primarily indicated for cholesterol management. It was part of a portfolio of generic drugs acquired by Cosmos Health in 2022 for $3.5 million, aimed at strengthening the company's presence in the global generics market and diversifying its pharmaceutical offerings for European and international distribution.

Brand names: Lipichol
Other names: Lipichol 2Lipichol2Lipichol-2

Beyond the preview

Go deeper on Lipichol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipichol.

Explore the full profile